Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JNJ and other ETFs, options, and stocks.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
131,900
Employees131,900
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
131,900
Employees131,900

JNJ Key Statistics

Market cap
367.45B
Market cap367.45B
Price-Earnings ratio
21.78
Price-Earnings ratio21.78
Dividend yield
3.15%
Dividend yield3.15%
Average volume
6.68M
Average volume6.68M
High today
$152.74
High today$152.74
Low today
$150.32
Low today$150.32
Open price
$150.84
Open price$150.84
Volume
963.56K
Volume963.56K
52 Week high
$175.97
52 Week high$175.97
52 Week low
$143.13
52 Week low$143.13

JNJ News

Seeking Alpha 17h
Shockwave Medical gains after HSR waiting period for sale to J&J expires

Shockwave Medical (NASDAQ:SWAV) rose 1.3% in after hours trading after the HSR waiting period for its planned sale to Johnson & Johnson (JNJ) expired. The HSR...

Shockwave Medical gains after HSR waiting period for sale to J&J expires
Seeking Alpha 2d
J&J-backed Rapport Therapeutics files for $100M IPO

Rapport Therapeutics (RAPP), which is backed by Johnson & Johnson's (JNJ) venture capital arm, has filed to raise around $100M through an initial public offerin...

J&J-backed Rapport Therapeutics files for $100M IPO
Yahoo Finance 2d
Johnson & Johnson's Dividend Analysis - Yahoo Finance

Exploring the Sustainability and Growth of Johnson & Johnson's Dividends Johnson & Johnson (NYSE:JNJ) recently announced a dividend of $1.24 per share, payable...

Johnson & Johnson's Dividend Analysis - Yahoo Finance

Analyst ratings

52%

of 23 ratings
Buy
47.8%
Hold
52.2%
Sell
0%

More JNJ News

Seeking Alpha 4d
Novo Nordisk, J&J lead R&D rankings in big pharma: report

Weight loss drugmaker Novo Nordisk (NVO) and U.S. healthcare giant Johnson & Johnson (NYSE:JNJ) have become the most transformative companies in big pharma, acc...

Novo Nordisk, J&J lead R&D rankings in big pharma: report
NBC News 4d
Study links talc use to ovarian cancer — a potential boon for thousands suing J&J - NBC News

New research published this week lends credence to the more than 50,000 lawsuits against Johnson & Johnson that allege its talc-based baby powder caused ovarian...

Study links talc use to ovarian cancer — a potential boon for thousands suing J&J - NBC News
Simply Wall St 5d
Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution

The fact that multiple Johnson & Johnson (NYSE:JNJ) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongs...

Johnson & Johnson Insiders Sell US$6.8m Of Stock, Possibly Signalling Caution
Reuters 5d
J&J-backed startup Rapport files for US IPO

(Reuters) -Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson, filed for an initial public offering in the U...

J&J-backed startup Rapport files for US IPO
Financial Times 5d
‘Reverse Yankee’ deals boom as Europe’s low borrowing costs lure US groups

Print this page US companies are flocking to Europe’s bond markets as an uptick in cross-border mergers and acquisitions and a rethink on the path of interest...

‘Reverse Yankee’ deals boom as Europe’s low borrowing costs lure US groups
Yahoo Finance 6d
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M - Yahoo Finance

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix...

Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M - Yahoo Finance
Yahoo Finance 6d
Johnson & Johnson Up 5.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance

A month has gone by since the last earnings report for Johnson & Johnson (JNJ). Shares have added about 5.5% in that time frame, underperforming the S&P 500. W...

Johnson & Johnson Up 5.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.